Info

OxiGene, Inc. is a clinical-stage, biopharmaceutical company developing therapeutics to treat cancer and eye diseases. The Company’s primary focus is the development and commercialization of product candidates referred to as vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in a number of ocular diseases, which are characterized by abnormal blood vessel growth. The Company's VDA product candidates act via a validated therapeutic mechanism, inhibition of blood flow to tumors and neovascular lesions within the eye. The Company's product candidates are ZYBRESTAT (generic name fosbretabulin, previously known as combretastatin A4 phosphate (CA4P)) and OXi4503, a second-generation VDA product.(Source: 10-K)